Background -The rebound increase in bronchial reactivity and fall in forced expiratory volume in one second (FEVI) following treatment with P agonists seen in several studies has occurred regardless of concurrent steroid therapy. Little is known about the effect of adding P agonists to corticosteroids, but in a recent study regular treatment with terbutaline appeared to reduce some of the beneficial effects of budesonide. The effects of budesonide alone and in combination with regular terbutaline treatment on lung function, symptom scores, and bronchial reactivity were therefore examined. Conclusions -Evening PEF was greater when budesonide was combined with regular terbutaline. There was no evidence of a difference in bronchial reactivity following the two treatment regimens. The findings of a previous study were not confirmed as the reduction in FEV1 after budesonide and terbutaline was smaller and not statistically significant. Further work is needed to determine whether this disparity in findings in the two studies is due to a type 2 statistical error in this study or a spurious finding in the previous study. (Thorax 1996;51:989-992) Keywords: agonists, corticosteroids, lung function.
about the effect of adding P agonists to corticosteroids, but in a recent study regular treatment with terbutaline appeared to reduce some of the beneficial effects of budesonide. The effects of budesonide alone and in combination with regular terbutaline treatment on lung function, symptom scores, and bronchial reactivity were therefore examined. Methods -Sixteen subjects with mild stable asthma inhaled budesonide 800 pg twice daily for two periods of 14 days with terbutaline 1000 jg three times daily or placebo in a double blind crossover fashion. FEVy and the dose of histamine or adenosine monophosphate (AMP) causing a 20% fall in FEV1 (PD20) were measured before and 12 hours after the final dose of treatment, and changes from baseline were compared. Seven day mean values for daily morning and evening peak expiratory flow (PEF) values, symptom scores, and rescue medication were compared before and during treatment. Results -Morning and evening PEF rose more with budesonide plus terbutaline than with budesonide alone, with a mean difference of 19 /min occurring in the evening (95% confidence interval (CI) 2 to 36). There was no difference in symptom scores during treatment. Following treatment the mean increase in FEV, was 150 ml higher with budesonide alone (95% CI -10 to 300). There was no difference between treatments in change in histamine and AMP PD20.
Conclusions -Evening PEF was greater when budesonide was combined with regular terbutaline. There was no evidence of a difference in bronchial reactivity following the two treatment regimens. The findings of a previous study were not confirmed as the reduction in FEV1 after budesonide and terbutaline was smaller and not statistically significant. Further work is needed to determine whether this disparity in findings in the two studies is due to a type 2 statistical error in this study or a spurious finding in the previous study. High doses of 1 agonists have been associated with epidemics of asthma deaths' and, in some studies, regular exposure to 13 agonists has had deleterious effects on lung function6'-and bronchial reactivity 911-15 once the acute bronchodilator effect has worn off. The mechanism of these effects is unclear but they appear to occur regardless of whether subjects are taking corticosteroids or not' and may even be greater in patients taking corticosteroids. " 7 Although inhaled [ agonists and corticosteroids are the mainstay of asthma treatment, relatively little is known about the interaction between these agents. Some early studies looked at the effect of adding a glucocorticoid to a P agonist and found an additive rather than synergistic interaction in acute dose response studies.'81'
The effect of adding regular P agonist therapy to inhaled steroids has not been studied in detail. In a recent study in which we examined the airway effects of budesonide alone and in combination with terbutaline, terbutaline appeared to reduce the beneficial effects of budesonide on lung function and its protection against the early response to allergen.20 A negative interaction between 13 agonists and steroids has also been seen at a molecular level in the human lung in vitro.2' A negative interaction could possibly explain some of the adverse effects of regular 1 agonist therapy. In this study we baseline values with both treatment regimens. The increase in morning PEF was similar for both treatments (42 versus 33 1/min for budesonide with and without terbutaline), whereas the increase in evening PEF was significantly greater after the combination of budesonide and terbutaline (33 versus 14 1/ min; mean difference 19 1/min (95% CI 2 to 36); p<0.05). The smaller increase in evening PEF with budesonide alone caused a trend towards greater reduction in diurnal variability in this group which was not significant. There was no difference in the change in daytime and night time symptom scores between treatment with budesonide alone and budesonide plus terbutaline. The distribution of symptom scores was skewed as several subjects had no symptoms during the study. The total score per week fell from 67 to 35 (median values 4 to 2 (daytime) and 4 to 0 (night time)) with budesonide alone and from 44 to 36 (median values 3 to 1 (daytime) and 1 to 0 (night time)) with budesonide plus terbutaline. Changes in the use ofipratropium did not differ significantly between treatments.
FEV1, PD20 HISTAMINE AND AMP
Changes in FEV1 and PD20 histamine and AMP after cessation of treatment are shown in table 2. Twelve hours after cessation oftherapy FEV, had increased significantly after budesonide alone (mean change 210ml (95% CI 100 to 320); p<0.01) but not after budesonide plus terbutaline (mean change 60 ml (95% CI -100 to 220); p >0.4), the difference being of borderline significance (mean difference 150ml (95% CI -10 to 300); p = 0.06). Both treatments led to an increase in both PD20 histamine and AMP with no significant differences between treatments for change in PD20 histamine (mean difference 0.34 doubling doses (95% CI -0.5 to 1.26); p>0.3) or PD20 AMP (mean difference 0.04 doubling doses (95 % CI -1.53 to 1.59); p>0.9).
Discussion
We have compared the airway response during and after two weeks oftreatment with budesonide given alone and in combination with regular terbutaline in subjects with mild asthma. Morning and evening PEF rose during both treatments with a significantly greater increase in evening PEF with the combined treatment.
Twelve hours after cessation of treatment FEV, was higher after budesonide alone, although the difference was not statistically significant (95% CI -10 to 300). There were na significant differences between regimens in symptoms during treatment or in change in bronchial reactivity to histamine or AMP after cessation of treatment.
This study was designed to explore the effect ofadding regular P agonist treatment to corticosteroid treatment following the unexpected finding in a recent parallel group study by Wong et al20 that some of the beneficial effects of budesonide were reduced by the concomitant use of terbutaline. In this earlier study evening PEF was higher in patients taking budesonide plus terbutaline, but following treatment FEVy and protection against the early response to antigen were greater after budesonide alone. 20 The studies differed in that reactivity was measured 12 hours after the last dose of treatment in this study compared with 33 hours in the study by Wong et al. 20 The present study does not therefore confirm a negative interaction between corticosteroids and [3 agonists. The difference between our present findings and those of Wong et al20 may be because our previous findings were spurious or may be due to differences in timing or, since the trend in the FEV1 in the present study was similar to that in our previous study, it might be due to a type 2 statistical error. On the basis of these findings and our previous study we cannot exclude the possibility that the efficacy of corticosteroids or the duration of their effect is reduced by concurrent treatment with a D agonist, although any effect is likely to be small, only apparent once the bronchodilator effect of the D agonist has worn off, and the optimum time to detect it has not been determined. This work was sponsored by a grant from the National Asthma Campaign. We thank Sarah Pacey (Clinical Trials Pharmacist) for handling the drugs and randomisation.
